A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

Overview

About this study

The purpose of this study is to assess the safety and efficacy of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male or female subjects between 15 and 75 years of age, inclusive. *note Mayo Clinic will only recruit/enroll patients 18 years of age or older. Approved by sponsor.
  • Primary diagnosis of narcolepsy with cataplexy.
  • Willing and able to comply with the study requirements.

Exclusion Criteria:

  • Other clinically significant conditions potentially causing EDS.
  • Clinically significant psychiatric disorders.

Eligibility last updated 11/22/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Lois Krahn, M.D.

Open for enrollment

Contact information:

Goddess White

(480) 574-2261

White.Goddess@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20526654

Mayo Clinic Footer